EUVIMEDEUVIMED entdecken
Crossref

Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists

Jagdish Chander Mohan, Amar Singhal, Abraham Oomman, Saumitra Ray, V T Shah, Baishali Nath, Deepak Bachani

Journal of the Association of Physicians of India · 2024

DOI: 10.59556/japi.72.0515 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Association of Physicians of India, 2024. Verfasst von Jagdish Chander Mohan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chairman and Head, Department of Cardiology, Jaipur Golden Hospital Hospital, Delhi, India. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Coronary Artery Disease, Cardiologists. Die Arbeit nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Coronary artery disease (CAD) management is one of the most significant facets of interventional cardiology. Evidence from several clinical trials has redefined the drug management of CAD, including optimizing the duration of antiplatelet treatment regimens in the management of CAD, which is an intricate clinical issue. The available evidence indicates that East Asians have a higher bleeding risk. However, the Indian phenotype differs from that of East Asians, making this data confounding when applied to clinical decision-making among Indian patients. There is a need for a close understanding of Indian interventional cardiologists' perceptions of complex decision-making pertaining to antiplatelet agents among Indian CAD patients in real-world clinical settings. AIM: This Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy (INDEPTH) study aims to assess the perspective of Indian interventional cardiologists regarding de-escalating from dual antiplatelet therapy (DAPT) to single antiplatelet therapy (SAPT), approach to decision-making, barriers, and related challenges in CAD management. METHODS: A cross-sectional knowledge, attitude, and practice (KAP) study survey was carried out among Indian interventional cardiologists practicing across different regions of India. A total of 209 responses were received. Descriptive statistics was used to summarize all the parameters. IBM Statistical Package for the Social Sciences (SPSS) statistics was used for biostatistical analysis. RESULTS: The study indicated that >90% of CAD patients received DAPT therapy immediately after percutaneous coronary intervention (PCI) (86.1%, p 12 months 94 (45%) of the respondents; 17 (8.1%) of the respondents reported it is 3-6 months, and lastly up to 3 months as per four (1.9%) of the respondents (p 12 months for low bleeding risk (65.6%, p 75% of the SAPT-eligible patients. (p 12 months for "low-bleeding" risk. One-third of respondents used clopidogrel as an antiplatelet agent in 50-75% of SAPT-eligible patients. Atorvastatin + clopidogrel is predominantly the most preferred combination of statin + SAPT for the management of CAD. Although the current international guidelines cover the Indian perspective to some extent, there is a need for Indian-specific guidelines on de-escalating from DAPT to SAPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsDual Anti-Platelet TherapyCoronary Artery DiseaseCardiologistsHumansIndiaCross-Sectional StudiesHealth Knowledge, Attitudes, PracticePractice Patterns, Physicians'Percutaneous Coronary InterventionFemaleMaleClinical Decision-Making

Substanzen

Platelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Chairman and Head, Department of Cardiology, Jaipur Golden Hospital Hospital, Delhi, India.
  • Senior Consultant, Department of Cardiology, Sri Balaji Action Medical Institute, Delhi, India.
  • Senior Consultant, Department of Cardiology, Apollo Hospitals, Chennai, Tamil Nadu, India.
  • Director, Department of Invasive Cardiology, AMRI Hospital, Kolkata, West Bengal, India.
  • Interventional Cardiologist, Department of Cardiology, SL Raheja Hospital, Mumbai, Maharashtra, India.
  • Medical Advisor, Department of Medical Affairs, Ajanta Pharma Limited, Mumbai, Maharashtra, India, Corresponding Author.

Zitieren

APA

Mohan, J. C., Singhal, A., Oomman, A., Ray, S., Shah, V. T., Nath, B., & Bachani, D. (2024). Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists. Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.72.0515

Vancouver

Mohan JC, Singhal A, Oomman A, Ray S, Shah VT, Nath B, et al. Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists. Journal of the Association of Physicians of India. 2024. doi:10.59556/japi.72.0515

BibTeX
@article{Mohan2024,
  author = {Mohan, Jagdish Chander and Singhal, Amar and Oomman, Abraham and Ray, Saumitra and Shah, V T and Nath, Baishali and Bachani, Deepak},
  title = {Indian Perspective on De-escalation from Dual Antiplatelet Therapy to Single Antiplatelet Therapy Study: A Knowledge, Attitude, and Practice Study among Indian Interventional Cardiologists},
  journal = {Journal of the Association of Physicians of India},
  year = {2024},
  doi = {10.59556/japi.72.0515}
}
Kostenlos starten →